An observational study in Aortic Valve Stenosis and Heart Valve Diseases, sponsored by Kumamoto University. Completed at 1 site in Japan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2018-10-02.
Sponsored by Kumamoto University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Aortic Valve Stenosis with a site in Japan — 4 open to participants now, 7 under way, none of them phase 3. Aortic Valve Stenosis · Japan.
Among the 19 studies in Aortic Valve Stenosis with a site in Japan, this one is the only one that started in 2017, is one of 4 observational ones, and was the 15th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →4 of the 19 studies in Aortic Valve Stenosis with a site in Japan are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Japan
Ages 18–100
Osaka University · Sites in Japan
OCEAN-SHD Study Group · Sites in Japan
Ages 20+
Edwards Lifesciences · Sites in Japan, United States, Australia and 3 more countries
Ages 65+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 20 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 64 across the 15 interventional studies, 803 across the 4 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 19 have an industry lead sponsor. The 10 most frequent:
Kumamoto University is the lead sponsor of 23 studies on the registry; 1 is open to participants now.
Kumamoto University has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Aortic Valve Stenosis with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06007222OCEAN-SHD Study GroupNon-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Aortic Valve Stenosis with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Transcatheter aortic valve implantation (TAVI) is well established, and can improve clinical outcomes of patients with severe aortic valve stenosis (AS) who are inoperable or have high surgical risk. Although the rates of periprocedural bleeding events are lower in TAVI compared to those in surgical aortic valve replacement, those in TAVI still remains high. In addition, current guideline recommended the dual antiplatelet (DAPT), clopidogrel plus aspirin, for a 3- to 6-month period after TAVI, however no evidences supports this approach. The antithrombotic regimen in patients undergoing TAVI is needed to be established.
To establish the antithrombotic regimen in patients undergoing TAVI,
Patients with severe symptomatic aortic valve stenosis, undergoing transcatheter aortic valve implantation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Changes in T-TAS parameters (AR-chip, PL-chip) during TAVI
To measure the thrombus formation area under the curve for AR-chip (AR10-AUC30), and PL-chip (PL24-AUC10) before and after TAVI.
Time frame: pre-, day 2, day 7, 1 month after device implantation
Changes in shear stress analyzed by using CFD analysis of contrast-enhanced CT
To measure the shear stress of aortic valve and aorta before and after TAVI by using CFD analysis of contrast-enhanced computed tomography (CT).
Time frame: pre-, day 7 after device implantation
Changes in von Willebrand factor multimer decrease
To measure the von Willebrand factor multimer decrease by using electrophoresis
Time frame: pre-, day 2 after device implantation
Periprocedural complication, particularly, bleeding complication defined by VARC-2 criteria.
Time frame: within 30 days after device implantation
Changes in plasma microRNAs
To measure the expression of plasma microRNAs before and after TAVI by using qPCR.
Time frame: pre-, day 2 after device implantation
Ran from Aug 2017 to primary completion in Apr 2018, 8 months.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's 8 months is below that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kumamoto University